Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLGGet Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 10,400 shares, a decline of 75.4% from the January 15th total of 42,300 shares. Approximately 2.0% of the company’s stock are short sold. Based on an average trading volume of 315,600 shares, the days-to-cover ratio is presently 0.0 days.

Bone Biologics Price Performance

BBLG traded down $0.40 during trading on Monday, hitting $3.75. The company had a trading volume of 61,752 shares, compared to its average volume of 119,819. The stock has a market capitalization of $1.47 million, a P/E ratio of -0.07 and a beta of 0.29. Bone Biologics has a one year low of $2.86 and a one year high of $96.00. The stock has a 50-day moving average of $3.81.

Bone Biologics (NASDAQ:BBLGGet Free Report) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($4.88) EPS for the quarter, topping the consensus estimate of ($24.32) by $19.44. Equities research analysts predict that Bone Biologics will post -25.84 earnings per share for the current year.

About Bone Biologics

(Get Free Report)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1.

Recommended Stories

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with's FREE daily email newsletter.